![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Show more
Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on...
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and...
Expands on previously reported data showing the halting of disease progression in patients with ALS at six months and a corresponding reduction in inflammation, oxidative stress, and enhanced...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.45 | 6.52173913043 | 6.9 | 7.55 | 6.85 | 24729 | 7.2723096 | CS |
4 | 1.31 | 21.6887417219 | 6.04 | 7.95 | 5.92 | 42025 | 7.07628377 | CS |
12 | -1.6 | -17.8770949721 | 8.95 | 9.72 | 5.76 | 50578 | 7.42400275 | CS |
26 | 1.35 | 22.5 | 6 | 10.6899 | 5.76 | 74019 | 8.50454236 | CS |
52 | 3.41 | 86.5482233503 | 3.94 | 10.6899 | 3.21 | 61302 | 7.21835466 | CS |
156 | 2.6 | 54.7368421053 | 4.75 | 10.6899 | 3.21 | 66933 | 6.32198939 | CS |
260 | 2.6 | 54.7368421053 | 4.75 | 10.6899 | 3.21 | 66933 | 6.32198939 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions